DDInter1852 DDInter899
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Treprostinil {u} (Compound) resembles {v} (Compound) Latanoprost
Treprostinil {u} (Compound) binds {v} (Gene) P2RY12
Treprostinil {u} (Compound) upregulates {v} (Gene) IL4R
Treprostinil {u} (Compound) is included by {v} (Pharmacologic Class) Vasodilation
Treprostinil {u} (Compound) downregulates {v} (Gene) CNDP2
Treprostinil {u} (Compound) causes {v} (Side Effect) Palpitations
Treprostinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Reteplase
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Treprostinil {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Treprostinil (Compound) resembles Latanoprost (Compound)
Treprostinil (Compound) binds P2RY12 (Gene)
Treprostinil (Compound) upregulates IL4R (Gene)
Treprostinil (Compound) is included by Vasodilation (Pharmacologic Class)
Treprostinil (Compound) downregulates CNDP2 (Gene)
Treprostinil (Compound) causes Palpitations (Side Effect)
Treprostinil may cause a minor interaction that can limit clinical effects when taken with Capsicum
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Reteplase
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Treprostinil may lead to a major life threatening interaction when taken with Ramucirumab